NZYM-001
Oral suspension - LPR

Therapeutic Area
Reflux
Program
NZYM-001
Oral suspension pepsin inhibitor
Oral suspension pepsin inhibitor
Details
Repurposing approach, using approved drug dosing and route of administration, fast-tracks program to phase III clinical trials to assess efficacy for LPR.
Status
Phase III
Indication
Laryngopharyngeal Reflux (LPR)
✓
Preclinical
✓
In vitro
✓
In vivo
Phase 3
Market